Literature DB >> 509385

Nodular malignant lymphomas: factors affecting complete response rate and survival.

F Cabanillas, T Smith, G P Bodey, J U Gutterman, E J Freireich.   

Abstract

The records of 109 patients with non-Hodgkin's lymphoma of nodular pattern were reviewed to determine which factors were associated with a favorable response to therapy and prolonged survival. A logistic regression model was utilized to identify the pertinent variables. Prognostic factors associated with a favorable response were, in order of decreasing importance: treatment with an Adriamycin combination regimen, absence of bulky tumor, and no exposure to prior chemotherapy. Thos associated with prolonged survival were: normal hemoglobin level, treatment with an Adriamycin combination regimen, female sex, and no prior exposure to therapy. Achievement of complete remission in these disorders resulted in a statistically longer duration of survival compared to partial responses or failures. Patients whose complete remission was induced with an Adriamycin-containing regimen and maintained with BCG immunotherapy had a significantly longer complete remission than those who did not receive BCG. Knowledge of these factors can be important in planning and analyzing future therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 509385     DOI: 10.1002/1097-0142(197912)44:6<1983::aid-cncr2820440604>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  The significance of the number of centroblasts in centroblastic/centrocytic lymphomas. A long term study in a large group of patients.

Authors:  W M Molenaar; H Bartels; J Koudstaal
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

2.  Are follicular large centrocytic and large centroblastic lymphomas one entity?

Authors:  W M Molenaar; J Koudstaal; H Bartels
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

3.  Histological, epidemiological and clinical aspects of centroblastic-centrocytic lymphomas subdivided according to the "working formulation".

Authors:  W M Molenaar; H Bartels; J Koudstaal
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.